Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2010
05/25/2010US7723339 signal transduction inhibitor is a PDGF receptor tyrosine kinase inhibitor or an active ingredient which decreases the activity of the epidermal growth factor; antiproliferative agent
05/25/2010US7723334 Highly selective norepinephrine reuptake inhibitors and methods of using the same
05/25/2010US7723323 fused 1,2,4-triazoles for modulating the activity of 11 beta -hydroxysteroid dehydrogenase type 1 (11 beta HSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions
05/25/2010US7723320 Use of estrogen compounds to increase libido in women
05/25/2010US7723304 Hypotensive agents; cardiovascular disorders; wound healing agents; antitumor agents; antidiabetic agents ; nephropathy; gastrointestinal disorders; alopecia; blood disorders ; urogenital disorders
05/25/2010US7723080 Murine α (1,3) fucosyltransferase Fuc-TVII, DNA encoding the same, method for preparing the same, antibodies recognizing the same, immunoassays for detecting the same, plasmids containing such DNA, and cells containing such a plasmid
05/25/2010US7723022 Oligonucleotide containing activated lymphocytes; antibody therap y; skin disorders; antiallergens; respiratory system disorders
05/25/2010US7722880 polynucleotide encodes a protein for inducing an immune response; use as vaccines; drug targeting to specific protein; bactericides; veterinary medicine
05/25/2010CA2489337C Indole derivatives useful as histamine h3 antagonists
05/25/2010CA2470476C Pyrrolidine and piperidine derivates as nk1 antagonists
05/25/2010CA2462922C Reverse-turn mimetics and method relating thereto
05/25/2010CA2433128C Novel quinuclidine derivatives and medicinal compositions containing the same
05/25/2010CA2421512C Cosmetic and pharmaceutical compositions and their use
05/25/2010CA2403423C Tri-aryl-substituted-ethane pde4 inhibitors
05/25/2010CA2376666C Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
05/25/2010CA2375923C Devices and compounds for treating arterial restenosis
05/25/2010CA2368621C Methods and compositions for treating solid tumors
05/25/2010CA2362279C Connective tissue softening
05/25/2010CA2326874C Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
05/20/2010WO2010056932A1 Pulsatile dosing of gossypol for treatment of disease
05/20/2010WO2010056575A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy
05/20/2010WO2010056574A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy
05/20/2010WO2010056223A1 Derivatives of hypoestoxides for the treatment of malaria
05/20/2010WO2010055950A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
05/20/2010WO2010055929A1 Novel hsp90-targeted anti-cancer chimeric peptide
05/20/2010WO2010055473A1 Methods of treating tumor cells using rhcc protein, fragment or variant
05/20/2010WO2010055340A1 Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
05/20/2010WO2010055081A1 Use of leukotriene inhibitors for treating lung diseases in prematurely born infants
05/20/2010WO2010054858A2 Polyvinylpyrrolidone as a therapeutically active compound for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens
05/20/2010WO2010054758A1 Synergistic pharmaceutical combination comprising an estrogen receptor antagonist and a progestin
05/20/2010WO2010030835A3 Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
05/20/2010US20100125131 Gene Encoding A Guanine Nucleotide Exchange Factor And The Gene Product Thereof
05/20/2010US20100125130 Tumour necrosis factor binding ligands
05/20/2010US20100125101 Immunostimulatory nucleic acid molecules
05/20/2010US20100125090 Modulators of ATP-Binding Cassette Transporters
05/20/2010US20100125070 Bupropion Metabolites and Methods of Their Synthesis and Use
05/20/2010US20100125063 Combinations of nicotinic acetylcholine alpha 7 receptor agonists
05/20/2010US20100124546 Adenovirus With Mutations in the Endoplasmic Reticulum Retention Domain of the E3-19K Protein and Their Use in Cancer Treatment
05/20/2010US20100124543 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
05/20/2010CA2743709A1 Treatment of proteinopathies using a farnesyl transferase inhibitor
05/20/2010CA2743295A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy
05/20/2010CA2743242A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy
05/20/2010CA2742824A1 Derivatives of hypoestoxides for the treatment of malaria
05/19/2010EP2186530A1 Promoters exhibiting endothelial cell specificity and methods of using same
05/19/2010EP2186529A2 Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal
05/19/2010EP2186524A1 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
05/19/2010EP2186521A1 Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
05/19/2010EP2186514A1 Treatment of Malignant Peripheral Nerve Sheath Tumors
05/19/2010EP2185202A1 Use of interleukin-22 in the treatment of fatty liver disease
05/19/2010EP1718337B1 New combinations of a 5-ht3 receptor antagonist with racecadotril or dexecadotril
05/19/2010EP1463487B1 Liposomal delivery of vitamin e based compounds
05/19/2010EP1461055B1 Anti-bacterial extracts from mammea americana
05/19/2010EP1438063B1 Glutation precursors for the treatment of neuropsychiatric disorders
05/19/2010EP1368060B1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
05/19/2010CN1957920B Anti cancer slow release agent carrying fluorouracil and synergist
05/19/2010CN1927175B Compound recipe anticancer slow release injection comprising tetrazole violet
05/19/2010CN1923173B Anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof
05/19/2010CN1923171B Compound recipe anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof
05/19/2010CN1875936B Anticancer sustained release agent containing clorfarabine and cytotoxic drug
05/19/2010CN101711160A Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue
05/19/2010CN101711159A oligo-guluronate and galacturonate compositions
05/19/2010CN101708338A Prodrug containing sterides structures and high dispersion preparation thereof
05/19/2010CN101708334A Medicament for treating animal dermatosis
05/19/2010CN101708165A Microspheres for active embolization
05/19/2010CN101708159A Preparation method for heat-sensitive medicament suspension
05/19/2010CN101130083B Ophthalmic composition, producing method and use of the same
05/18/2010US7718824 Therapeutic stem cell growth factor composition, anti-inflammatory composition, and uses thereof
05/18/2010US7718772 Canine thymic stromal lymphopoietin protein and uses thereof
05/18/2010US7718705 administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetin or salt to a male human to treat sexual dysfunction e.g. premature ejaculation
05/18/2010US7718702 Cannabinoid receptor ligands
05/18/2010US7718694 Compositions and methods for therapy for diseases characterized by defective chloride transport
05/18/2010US7718670 antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; reaction with organometallic derivative
05/18/2010US7718643 Pharmaceutical formulation
05/18/2010US7718623 Immunostimulatory oligonucleotide that induces interferon alpha
05/18/2010US7718606 Methods for treating muscle diseases and disorders
05/18/2010US7718200 Plant extract mixtures and their uses
05/18/2010US7718197 Colonic purgative composition with soluble binding agent
05/18/2010US7718192 Tamper-resistant oral opioid agonist formulations
05/18/2010US7718190 Self forming, thermodynamically stable liposomes and their applications
05/18/2010US7718180 Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site
05/18/2010US7718177 Antibodies directed to fragments of connective tissue growth factor (CTGF) polypeptide and methods and uses thereof
05/18/2010US7718161 Method for treating a motoneuron disorder
05/18/2010US7718128 Kit including a cucurbit(6-10)uril derivative bound to a first material; and a second component that is a ligand that non-covalently binds to the cucurbituril bound to a second material; materials include biomolecules, drugs, catalysts, chromophores, fluorescent materials, phosphors, and cyclophanes
05/18/2010CA2472475C 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
05/18/2010CA2422371C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2422367C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2401498C New self emulsifying drug delivery system
05/18/2010CA2382465C Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
05/18/2010CA2259143C G-beta-gamma regulated phosphatidylinositol-3' kinase p101 regulatory subunit
05/14/2010WO2010054125A1 Formulations and uses of 24r, 25-dihydroxyvitamin d3 as an anti-apoptotic
05/14/2010WO2010053350A1 Inhibition of viral infection and replication by mesenchymal stem cells (msc) and msc-derived products
05/14/2010WO2010053068A1 Novel useful therapeutic agent for lower urinary tract symptom
05/14/2010WO2010052508A1 Ligands of vitamin d nuclear receptors with cell maturation promotion factors
05/13/2010US20100120800 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
05/13/2010US20100120743 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds
05/13/2010US20100120734 Formoterol/steroid bronchodilating compositions and methods of use thereof
05/13/2010US20100120688 ErbB Interface Peptidomimetics And Methods Of Use Thereof
05/13/2010US20100120070 Precise efficacy assay methods for active agents including chemotherapeutic agents
05/13/2010US20100119559 Dosage forms of risedronate
05/13/2010US20100119551 Methods and reagents for vaccination which generate a CD8 T cell immune response
1 ... 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 ... 1151